Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

2874 BAND 3CEINGE (Gly796Arg) Mutation Causes Dehydrated Hereditary Stomatocytosis (DHS) with Dyserythropoietic Phenotype

Sunday, December 7, 2008, 6:00 PM-8:00 PM
Hall A (Moscone Center)
Poster Board II-968

Luigia De Falco1*, Lucia De Franceschi2*, Frank Borgese3*, Carmelo Piscopo4*, Maria Rosaria Esposito4*, Rosa Anna Avvisati4*, Pietro Izzo5*, Helene Guizouarn3*, Andrea Biondani2* and Achille Iolascon, MD, PhD4

1Medical Genetics - University Federico II Naples, CEINGE Scarl, Napoles, Italy
2Medicina Interna, Università di Verona
3Université de Nice, Bâtiment de Sciences Natur, aLaboratoire de Biologie et Physiopathologie des Systèmes Intégrés, FRE3094, CNRS-, Nice, France
4Università degli Studi di Napoli, "Federico II", Ceinge, scarl, Naples, Italy
5Medicina Interna, Università di Bari, Bari

Stomatocytosis is an inherited autosomal dominant hemolytic anemia and includes overhydrated hereditary stomatocytosis (OHS), dehydrated hereditary stomatocytosis (DHS), hereditary cryohydrocytosis (CHC) and familial pseudohyperkalemia (FP).
Here, we report a novel variant of hereditary stomatocytosis  due to a de-novo band 3 mutation due to G>A transition at nucleotide 2500 in exon 17 (p. G796R, band3CEINGE) associated with dyserythropoietic phenotype. This 43-years-old Caucasian female (II-2) with unrelated parents was admitted to our hospital for mild anemia evaluation. The patient was in good health until 7 years when she frequently experienced asthenia. Anemia was first recognized at the age of eighth years with presence of jaundice and hyperchromic urine, but she had never received blood transfusions.
We observed a mild hypochromic macrocytic anemia with a hemoglobin level of  11.5 g/dL, a mean cell volume (MCV) of  110 fL, and a mean hemoglobin concentration (MCH) of 36.1 pg, the reticulocyte count was 64 x 103/µL. There was a typical hemolytic features:  high levels of indirect bilirubin (3.48 mg/dL) and lactate dehydrogenase ( 567 U/l, v.n. 240- 480 U/l ) with negativity at direct and indirect Coomb’s test .
Spleen was enlarged and ultrasonography detected 15 cm of longitudinal size. She was cholecystectomized at the age of 14 years because of numerous symptomatic small stones. Serum iron, soluble transferrin receptor, serum ferritin and transferrin saturation levels were all increased, while the transferrin was in the normal range.
Other blood tests including osmotic fragility with incubated and fresh erythrocytes, serum electrolytes, B12 and folate levels, erythrocyte enzyme levels, EMA test and Pink test were normal.
Peripheral blood smear showed anisopoikilocytosis with rare stomatocytes and no spherocytes. Bone marrow aspirate showed remarkable dyserythropoiesis with increased number of erythroblasts and binucleate erythroblasts, basophilic erythroblasts with alterations, irregular nuclei maturation, intererythroblastic bridges and erythroblasts with basophilic stippling.  She received  since the age of 14 yrs a diagnosis for congenital dyserythropoietic anemia type I.
Patients red cells showed (i) increase Na+ content and decrease K+ content; (ii) reduced Na-K pump activity and (iii) increased Na-H exchange, NKCC cotransport and KCC cotransport activities. We then functionally characterized band 3 CEINGE in Xenopus oocytes, showing that the mutated band 3 is converted from anion exchanger (Cl-, HCO3-) function to unregulated cation pathway for Na+ and K+. The mutated band 3 was also associated with increased tyrosine phosphorylation pattern of some red cell membrane proteins.
During erythropoiesis band 3 protein is the last cytoskeletal protein to appear, thus the dyserythropoietic phenotype may be related to a possible role of the mutated band 3 in perturbation of cytoskeleton assembly in the late stage of erythropoiesis, allowing us to conclude for a new variant of stomatocytosis with dyserythropoietic phenotype.

Disclosures: No relevant conflicts of interest to declare.

Previous Presentation | Next Presentation >>

*signifies non-member of ASH